Global CRO Icon has partnered with Mereo BioPharma Group, a recently formed specialty biopharmaceutical company. Icon will be the sole provider of clinical development services to Mereo. 

Mereo is a new U.K. company that is focused on acquiring, rapidly developing and commercializing innovative medicines that are targeted at rare and specialist disease areas. The company’s initial portfolio consists of clinical-stage products acquired from Novartis and are targeted at brittle bone syndrome, acute exacerbations of chronic obstructive pulmonary disease and hypogonadotropic hypogonadism.